Capsule Endoscopy is the fastest-growing product line in gastrointestinal endoscopy, compounding at 10.2% a year and taking ground from GI Videoscopes, whose share of revenue falls from 31.99% in 2025 to 29.02% by 2034. Capsule Endoscopy's own share rises from 11% to 14%, and its value from USD 5.96 billion to USD 14.42 billion.
Market size and what is pulling it
The global gastrointestinal endoscopy device market was valued at USD 54.2 billion in 2025. It is projected to grow from USD 58.65 billion in 2026 to USD 103.03 billion by 2034, a compound annual growth rate of 7.3% over the forecast period. Contrive Datum Insights presents these findings in its Gastrointestinal Endoscopy Device Market report, covering 2026-2034.
The devices in scope include videoscopes, imaging processors, biopsy and resection instruments, hemostasis tools and the accessories used alongside them. Buyers are hospital endoscopy departments, ambulatory surgical centers and specialty clinics.
Capsule Endoscopy outruns the market because of where demand originates. The study rates the rising global burden of colorectal and GI cancers, and the screening volumes that follow, as the largest single contributor to growth, with a high impact. A swallowed imaging capsule suits a screening workflow, and the figures show it: 10.2% against a market average of 7.3%.
Other lines in the report point the same way. By usage, Single-Use (Disposable) grows fastest at 11.91%, against a 71% share for Reusable in 2025. By end user, Ambulatory Surgical Center grows fastest at 10.09%, while Hospitals led in 2025 with 68.01% of revenue. By application, Therapeutic grows fastest at 8.44%, though Diagnostic led with 56%.
In the study's bull case, faster adoption of single-use endoscopes and accelerated screening-program rollouts in Asia Pacific lift procedure volumes above the base case, taking 2034 revenue to USD 118.48 billion.
On the regional picture, North America was the largest region in 2025 at 36.5% of global revenue, or USD 19.79 billion, and reaches USD 34 billion by 2034. Asia Pacific gains share, from 27% in 2025 to 32.5% in 2034, as revenue grows from USD 14.63 billion to USD 33.48 billion. Middle East and Africa stays the smallest region throughout, at 5.2% of 2025 revenue and 4.7% by 2034. The United States is the largest single country market at USD 17.42 billion in 2025, or 32.14% of global revenue.
The largest line grows slowest
The biggest segment sets the counterweight. GI Videoscopes carries 31.99% of 2025 revenue, worth USD 17.34 billion, yet grows at only 6.13%, below the market's 7.3%. It stays the largest product line through 2034, but a growing share of new revenue is going elsewhere.
The bear case shows how exposed the sector is to buyer budgets. Slower hospital capital spending and delayed screening-program funding in price-sensitive markets would hold procedure volume growth below the base case and limit 2034 revenue to USD 91.7 billion. Medical Stores & Brand Outlet led the sales channel axis in 2025 with 81.99% of revenue at USD 44.44 billion, while Online Retailing grows fastest at 10.88%.
The report segments the market across five axes: product, sales channel, end user, usage and application. It gives revenue and a growth rate for every line in every year from 2020 to 2034, and covers all five regions with country-level breakdowns, the competitive landscape and the research methodology. It is delivered as a PDF, and a free sample is available on request.